Ken Griffin Profound Medical Corp. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Profound Medical Corp. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,200 shares of PROF stock, worth $8,376. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,200

Holding current value

$8,376

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$7.47 - $11.18 $201,279 - $301,245	26,945 New	26,945 $214,000
Q1 2024 May 15, 2024	SELL	$7.3 - $9.46 $66,510 - $86,190	-9,111 Reduced 46.21%	10,607 $90,000
Q4 2023 Feb 14, 2024	BUY	$7.85 - $11.18 $147,650 - $210,284	18,809 Added 2069.2%	19,718 $167,000
Q3 2023 Nov 14, 2023	SELL	$7.91 - $13.27 $89,264 - $149,751	-11,285 Reduced 92.55%	909 $9,000
Q2 2023 Aug 14, 2023	BUY	$9.27 - $14.88 $113,038 - $181,446	12,194 New	12,194 $158,000
Q4 2021 Feb 14, 2022	BUY	$10.38 - $15.2 $67,833 - $99,332	6,535 Added 24.38%	33,343 $374,000
Q3 2021 Nov 15, 2021	SELL	$13.6 - $17.88 $76,690 - $100,825	-5,639 Reduced 17.38%	26,808 $392,000
Q2 2021 Aug 16, 2021	SELL	$16.0 - $20.59 $791,456 - $1.02 Million	-49,466 Reduced 60.39%	32,447 $530,000
Q1 2021 May 17, 2021	BUY	$19.16 - $28.09 $922,324 - $1.35 Million	48,138 Added 142.53%	81,913 $1.65 Million
Q4 2020 Feb 16, 2021	BUY	$16.4 - $22.9 $175,348 - $244,846	10,692 Added 46.32%	33,775 $694,000
Q3 2020 Nov 16, 2020	BUY	$14.05 - $18.13 $324,316 - $418,494	23,083 New	23,083 $407,000
Q2 2020 Aug 14, 2020	SELL	$9.41 - $16.94 $180,991 - $325,823	-19,234 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$6.88 - $19.7 $132,329 - $378,909	19,234 New	19,234 $187,000

Others Institutions Holding PROF

# of Institutions

Shares Held

8.93M

Call Options Held

1.2K

Put Options Held

View Full List

About Profound Medical Corp.

Ticker PROF
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 20,851,300
Market Cap $146M
Description
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for...

More about PROF

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account